Insamo

Insamo, Inc., based in Berkeley, CA, is a global biotechnology company focused on revolutionizing drug discovery for some of the most challenging diseases. The company leverages a pioneering platform that automates the design, synthesis, and testing of drug candidates at an unprecedented scale. By utilizing trillions of proprietary experimental data points, Insamo iterates its design cycle across a vast chemical space, setting a new standard for scalable machine learning in drug design. The company's groundbreaking approach is particularly notable for its focus on discovering membrane permeable and orally available cyclic peptides, which have antibody-like binding affinity. Insamo serves pharmaceutical companies and research institutions looking for innovative solutions in drug development. The business operates in the biotechnology and pharmaceutical markets, employing a business model that includes partnerships, licensing agreements, and direct sales of its proprietary compounds. Revenue is generated through these collaborations and the commercialization of its drug discovery platform.

Keywords: biotechnology, drug discovery, scalable machine learning, cyclic peptides, pharmaceutical, membrane permeable, oral availability, antibody-like affinity, proprietary data, automated synthesis.